Compare Google Inc (GOOG) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Google Inc vs Novo Nordisk A/S — how do they compare? Google Inc trades at $342.25 (market cap $4.20T), while Novo Nordisk A/S trades at $46.46 (market cap $207.85B). The key difference: Google Inc is far larger — about 20.2× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| GOOG | NVO | |
|---|---|---|
Market Cap | $4.20T | $207.85B |
Volume | 1,511,127 | — |
Sector | Technology | Health |
52-Week High | $399.06 | $63.98 |
52-Week Low | $200.19 | $35.29 |
Enterprise Value | $4.09T | $222.55B |
Dividend Yield | 0.26% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $342.71, down 3.69% on the day, with technical indicators showing a bearish trend near support at $340. The company reported strong fundamentals with Q2 2026 EPS of $9.11 beating expectations, revenue growth to $402.84B in 2025, and robust profitability margins. Recent news highlights AI advancements, including Gemini reaching 1 billion users, but also regulatory scrutiny from French media.
The stock presents a compelling long-term opportunity with a consensus price target of $431.67, representing 26% upside, supported by 87% analyst buy ratings. Risks include high capital expenditure forecasts up to $205B for 2026, competitive AI pressures, and ongoing regulatory challenges. Investors should weigh strong cash flow generation against aggressive investment cycles.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
